Provided by Tiger Trade Technology Pte. Ltd.

AC Immune SA

2.90
+0.26009.85%
Post-market: 2.83-0.0699-2.41%19:30 EDT
Volume:442.01K
Turnover:1.26M
Market Cap:295.14M
PE:-5.51
High:2.95
Open:2.66
Low:2.65
Close:2.64
52wk High:4.00
52wk Low:2.03
Shares:101.77M
Float Shares:39.19M
Volume Ratio:2.61
T/O Rate:1.13%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5264
EPS(LYR):-0.8828
ROE:-78.53%
ROA:-16.04%
PB:6.73
PE(LYR):-3.29

Loading ...

AC Immune reports Phase 1 in vivo brain imaging data for TDP-43 PET tracer ACI-19626

Reuters
·
Mar 19

AC Immune Presents First in Vivo Images of Brain Tdp-43 Pathology From Phase 1 Trial of Pet Tracer ACI-19626, at Ad/Pdtm 2026

THOMSON REUTERS
·
Mar 19

AC Immune SA director Roy Ervin Twyman files initial beneficial ownership statement

Reuters
·
Mar 19

AC Immune SA CEO and Director Andrea Pfeifer Files Initial Beneficial Ownership Statement

Reuters
·
Mar 19

AC Immune Price Target Maintained With a $8.00/Share by BTIG

Dow Jones
·
Mar 16

AC Immune SA reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 13

AC Immune Q4 EPS $(0.17) Beats $(0.19) Estimate, Sales $422.914K

Benzinga Earnings
·
Mar 13

AC Immune reports FY25 EPS (CHF 0.70) vs (CHF 0.51) last year

TIPRANKS
·
Mar 13

AC Immune FY2025 contract revenue fell 87% to CHF 3.57 million as net loss widened 38% to CHF 70.45 million

Reuters
·
Mar 13

AC Immune Sa - Expects Total Cash Expenditure for Full Year 2026 to Be CHF 55-65 Mln

THOMSON REUTERS
·
Mar 13

AC Immune Sa: Cash Resources of CHF 91.4 Mln as of December 31, 2025, Provide Funding to End of Q3 2027

THOMSON REUTERS
·
Mar 13

Press Release: AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update

Dow Jones
·
Mar 13

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 11

Swiss stocks - Factors to watch on March 11

Reuters
·
Mar 11

AC Immune SA expected to post a loss of 17 rappen a share - Earnings Preview

Reuters
·
Mar 09

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 09

AC Immune to host Parkinson’s disease precision prevention symposium and present TDP-43 PET-tracer data at AD/PD 2026

Reuters
·
Mar 05

BRIEF-AC Immune Initiates Phase 1 Clinical Trial Of NLRP3 Inhibitor

Reuters
·
Feb 24

AC Immune doses first participant in Phase 1 trial of NLRP3 inhibitor ACI-19764

Reuters
·
Feb 24

AC Immune Initiates Phase 1 Clinical Trial of Nlrp3 Inhibitor

THOMSON REUTERS
·
Feb 24